NEW YORK, March 01, 2018 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Ohr Pharmaceutical, Inc. ("Ohr") (NASDAQ:OHRP) securities between June 24, 2014 and January 4, 2018.
Click here to learn about the case: http://www.wongesq.com/pslra-c/ohr-pharmaceutical-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Ohr’s lead product Squalamine would not produce vision improvements and was commercially not viable; and (2) as a result of the foregoing, Defendants’ statements about Ohr’s business, operations, and prospects were misleading and/or lacked a reasonable basis.
If you suffered a loss in Ohr you have until April 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/ohr-pharmaceutical-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]


Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
OpenAI Restricts Astra AI Over Cyberattack Risks
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 



